Official Title
Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY): Registry of Patient-level Clinical Data on CytoSorb Hemoadsorption Provided Via Integration of the CytoSorb Device Into Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), or Hemoperfusion Extracorporeal Circuits in COVID-19 ICU Patients
Brief Summary

The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.

Status
Completed
Conditions
COVID-19
Interventions

Device: CytoSorb 300 mL device

CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.

Eligibility Criteria

Inclusion Criteria:

1. Confirmed COVID-19

2. Provision of CytoSorb therapy per Instructions for Use (IFU) of the CytoSorb device.

Exclusion Criteria:

1. CytoSorb therapy for diseases other than COVID-19

2. Survival unlikely within 24 hours (for prospectively enrolled patients)

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

Medical Center of Aurora
Aurora, Colorado, United States

University of Chicago Medicine
Chicago, Illinois, United States

Franciscan Health Indianapolis
Indianapolis, Indiana, United States

Baptist Memorial Hospital
Southaven, Mississippi, United States

New York University Medical Center
New York, New York, United States

West Virginia University
Morgantown, West Virginia, United States

Medical College of Wisconsin
Milwaukee, Wisconsin, United States

Investigators

Peter Nelson, MD, Study Director
CytoSorbents Corporation

Sponsors / Collaborators
CytoSorbents Europe GmbH
NCT Number
NCT04391920
MeSH Terms
COVID-19